{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["bioavailability", "cannabidiol (CBD)", "endocannabinoid system", "pharmacokinetics", "tetrahydrocannabinol (THC)"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37375550", "DateCompleted": {"Year": "2023", "Month": "06", "Day": "29"}, "DateRevised": {"Year": "2023", "Month": "07", "Day": "01"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "06", "Day": "06"}], "Language": ["eng"], "ELocationID": ["2646", "10.3390/nu15122646"], "Journal": {"ISSN": "2072-6643", "JournalIssue": {"Volume": "15", "Issue": "12", "PubDate": {"Year": "2023", "Month": "Jun", "Day": "06"}}, "Title": "Nutrients", "ISOAbbreviation": "Nutrients"}, "ArticleTitle": "THC-Reduced <i>Cannabis sativa</i> L.-How Does the Solvent Determine the Bioavailability of Cannabinoids Given Orally?", "Abstract": {"AbstractText": ["The bioavailability levels of cannabidiol (CBD) and tetrahydrocannabinol (THC) determine their pharmacological effects. Therefore, for medical purposes, it is essential to obtain extracts containing the lowest possible content of the psychogenic component THC. In our extract, the CBD/THC ratio was 16:1, which is a high level compared to available medical preparations, where it is, on average, 1:1. This study assessed the bioavailability and stability of CBD and THC derived from <i>Cannabis sativa</i> L. with reduced THC content. The extract was orally administered (30 mg/kg) in two solvents, Rapae oleum and Cremophor, to forty-eight Wistar rats. The whole-blood and brain concentrations of CBD and THC were measured using liquid chromatography coupled with mass spectrometry detection. Much higher concentrations of CBD than THC were observed for both solvents in the whole-blood and brain after oral administration of the <i>Cannabis sativa</i> extract with a decreased THC content. The total bioavailability of both CBD and THC was higher for Rapae oleum compared to Cremophor. Some of the CBD was converted into THC in the body, which should be considered when using <i>Cannabis sativa</i> for medical purposes. The THC-reduced hemp extract in this study is a promising candidate for medical applications."]}, "AuthorList": [{"Identifier": ["0000-0002-8347-0512"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Physiology Department, Poznan University of Medical Sciences, ul. \u015awi\u0119cickiego 6, 61-861 Pozna\u0144, Poland."}], "LastName": "Bartkowiak-Wieczorek", "ForeName": "Joanna", "Initials": "J"}, {"Identifier": ["0000-0002-0081-6558"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Physiology Department, Poznan University of Medical Sciences, ul. \u015awi\u0119cickiego 6, 61-861 Pozna\u0144, Poland."}], "LastName": "M\u0105dry", "ForeName": "Edyta", "Initials": "E"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Cannabitey s.c. Pozna\u0144, ul. Uniwersytetu Pozna\u0144skiego 10/B123, 61-614 Pozna\u0144, Poland."}], "LastName": "Ksi\u0105\u017ckiewicz", "ForeName": "Micha\u0142", "Initials": "M"}, {"Identifier": ["0000-0003-1415-6252"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Physiology Department, Poznan University of Medical Sciences, ul. \u015awi\u0119cickiego 6, 61-861 Pozna\u0144, Poland."}], "LastName": "Winkler-Galicki", "ForeName": "Jakub", "Initials": "J"}, {"Identifier": ["0000-0003-1500-8251"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biotechnology, Institute of Natural Fibres and Medicinal Plants National Research Institute, Wojska Polskiego 71B, 60-630 Pozna\u0144, Poland."}], "LastName": "Szalata", "ForeName": "Milena", "Initials": "M"}, {"Identifier": ["0000-0002-0153-4317"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry and Biotechnology, Pozna\u0144 University of Life Sciences, ul. Dojazd 11, 60-632 Pozna\u0144, Poland."}], "LastName": "Szalata", "ForeName": "Marlena", "Initials": "M"}, {"Identifier": ["0009-0000-3717-8329"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Neuromed Consultorios, Jos\u00e9 Ibarra Olivares 106, Centro, Pachuca de Soto 42000, Hidalgo, Mexico."}, {"Identifier": [], "Affiliation": "Centro M\u00e9dico Privado Sanatorio Ortega, Jos\u00e9 Ibarra Olivares 105, Centro, Pachuca de Soto 42000, Hidalgo, Mexico."}], "LastName": "Jim\u00e9nez", "ForeName": "Ulises Elizalde", "Initials": "UE"}, {"Identifier": ["0000-0003-0629-2991"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Szpitalna Street 27/33, 60-572 Pozna\u0144, Poland."}], "LastName": "Wielgus", "ForeName": "Karolina", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences, ul. Rokietnicka 3, 60-806 Pozna\u0144, Poland."}], "LastName": "Grze\u015bkowiak", "ForeName": "Edmund", "Initials": "E"}, {"Identifier": ["0000-0001-5601-7002"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biotechnology, Institute of Natural Fibres and Medicinal Plants National Research Institute, Wojska Polskiego 71B, 60-630 Pozna\u0144, Poland."}], "LastName": "S\u0142omski", "ForeName": "Ryszard", "Initials": "R"}, {"Identifier": ["0000-0001-7272-5738"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences, ul. Rokietnicka 3, 60-806 Pozna\u0144, Poland."}], "LastName": "Bienert", "ForeName": "Agnieszka", "Initials": "A"}], "GrantList": [{"GrantID": "INNOMED/I/11/NCBR/2014", "Agency": "The National Centre for Research and Development", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Nutrients", "NlmUniqueID": "101521595", "ISSNLinking": "2072-6643"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Cannabinoids"}, {"RegistryNumber": "39279-69-1", "NameOfSubstance": "cremophor"}, {"RegistryNumber": "0", "NameOfSubstance": "Solvents"}, {"RegistryNumber": "19GBJ60SN5", "NameOfSubstance": "Cannabidiol"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Oils"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Cannabinoids"}, {"QualifierName": ["chemistry"], "DescriptorName": "Cannabis"}, {"QualifierName": [], "DescriptorName": "Solvents"}, {"QualifierName": [], "DescriptorName": "Biological Availability"}, {"QualifierName": [], "DescriptorName": "Rats, Wistar"}, {"QualifierName": [], "DescriptorName": "Cannabidiol"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plant Extracts"}, {"QualifierName": [], "DescriptorName": "Plant Oils"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Lu H.-C., Mackie K. Review of the Endocannabinoid System. Biol. Psychiatry Cogn. Neurosci. Neuroimaging. 2021;6:607\u2013615. doi: 10.1016/j.bpsc.2020.07.016.", "ArticleIdList": ["10.1016/j.bpsc.2020.07.016", "PMC7855189", "32980261"]}, {"Citation": "Zuardi A.W. History of cannabis as a medicine: A review. Rev. Bras. De Psiquiatr. 2006;28:153\u2013157. doi: 10.1590/S1516-44462006000200015.", "ArticleIdList": ["10.1590/S1516-44462006000200015", "16810401"]}, {"Citation": "Bridgeman M.B., Abazia D.T. Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting. PTA Peer-Rev. J. Formul. Manag. 2017;42:180\u2013188.", "ArticleIdList": ["PMC5312634", "28250701"]}, {"Citation": "Poyatos L., P\u00e9rez-Acevedo A.P., Papaseit E., P\u00e9rez-Ma\u00f1\u00e1 C., Martin S., Hladun O., Siles A., Torrens M., Busardo F.P., Farr\u00e9 M. Oral Administration of Cannabis and \u0394-9-tetrahydrocannabinol (THC) Preparations: A Systematic Review. Medicina. 2020;56:309. doi: 10.3390/medicina56060309.", "ArticleIdList": ["10.3390/medicina56060309", "PMC7353904", "32585912"]}, {"Citation": "Panlilio L.V., Justinova Z., Goldberg S.R. Animal models of cannabinoid reward. Br. J. Pharmacol. 2010;160:499\u2013510. doi: 10.1111/j.1476-5381.2010.00775.x.", "ArticleIdList": ["10.1111/j.1476-5381.2010.00775.x", "PMC2931551", "20590560"]}, {"Citation": "Pagano C., Navarra G., Coppola L., Avilia G., Bifulco M., Laezza C. Cannabinoids: Therapeutic Use in Clinical Practice. Int. J. Mol. Sci. 2022;23:3344. doi: 10.3390/ijms23063344.", "ArticleIdList": ["10.3390/ijms23063344", "PMC8952215", "35328765"]}, {"Citation": "Doohan P.T., Oldfield L.D., Arnold J.C., Anderson L.L. Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: A Full-Spectrum Characterization. AAPS J. 2021;23:91. doi: 10.1208/s12248-021-00616-7.", "ArticleIdList": ["10.1208/s12248-021-00616-7", "34181150"]}, {"Citation": "Abouchedid R., Ho J.H., Hudson S., Dines A., Archer J.R.H., Wood D.M., Dargan P.I. Acute Toxicity Associated with Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists with Analytical Confirmation. J. Med. Toxicol. 2016;12:396\u2013401. doi: 10.1007/s13181-016-0571-7.", "ArticleIdList": ["10.1007/s13181-016-0571-7", "PMC5135680", "27456262"]}, {"Citation": "Kiselak T.D., Koerber R., Verbeck G.F. Synthetic route sourcing of illicit at home cannabidiol (CBD) isomerization to psychoactive cannabinoids using ion mobility-coupled-LC\u2013MS/MS. Forensic Sci. Int. 2020;308:110173. doi: 10.1016/j.forsciint.2020.110173.", "ArticleIdList": ["10.1016/j.forsciint.2020.110173", "32028121"]}, {"Citation": "Lucas C.J., Galettis P., Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br. J. Clin. Pharmacol. 2018;84:2477\u20132482. doi: 10.1111/bcp.13710.", "ArticleIdList": ["10.1111/bcp.13710", "PMC6177698", "30001569"]}, {"Citation": "Ramella A., Roda G., Pavlovic R., Cas M.D., Casagni E., Mosconi G., Cecati F., Minghetti P., Grizzetti C. Impact of Lipid Sources on Quality Traits of Medical Cannabis-Based Oil Preparations. Molecules. 2020;25:2986. doi: 10.3390/molecules25132986.", "ArticleIdList": ["10.3390/molecules25132986", "PMC7412533", "32629796"]}, {"Citation": "Van Zuylen L., Verweij J., Sparreboom A. Role of Formulation Vehicles in Taxane Pharmacology. Investig. New Drugs. 2001;19:125\u2013141. doi: 10.1023/A:1010618632738.", "ArticleIdList": ["10.1023/A:1010618632738", "11392447"]}, {"Citation": "Cannabis-based medicines\u2014GW pharmaceuticals: High CBD, high THC, medicinal cannabis\u2014GW pharmaceuticals, THC:CBD. Drugs RD. 2003;4:306\u2013309. doi: 10.2165/00126839-200304050-00005.", "ArticleIdList": ["10.2165/00126839-200304050-00005", "12952500"]}, {"Citation": "Cessak G. Polish Pharmacopoeia. xth ed. Office for Registration of Medicinal Products Medical Devices and Biocidal Products; Warsaw, Poland: 2014. pp. 1\u20132."}, {"Citation": " [(accessed on 1 May 2023)].  Available online:  https://www.sigmaaldrich.com/PL/pl/product/mm/238470."}, {"Citation": "Szalata M., Dreger M., Zieli\u0144ska A., Banach J., Szalata M., Wielgus K. Simple Extraction of Cannabinoids from Female Inflorescences of Hemp (Cannabis sativa L.) Molecules. 2022;27:5868. doi: 10.3390/molecules27185868.", "ArticleIdList": ["10.3390/molecules27185868", "PMC9504406", "36144607"]}, {"Citation": "Deiana S., Watanabe A., Yamasaki Y., Amada N., Arthur M., Fleming S., Woodcock H., Dorward P., Pigliacampo B., Close S., et al. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), \u03949-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive\u2013compulsive behaviour. Psychopharmacology. 2011;219:859\u2013873. doi: 10.1007/s00213-011-2415-0.", "ArticleIdList": ["10.1007/s00213-011-2415-0", "21796370"]}, {"Citation": "Viudez-Mart\u00ednez A., Garc\u00eda-Guti\u00e9rrez M.S., Navarr\u00f3n C.M., Morales-Calero M.I., Navarrete F., Torres-Su\u00e1rez A.I., Manzanares J. Cannabidiol reduces ethanol consumption, motivation and relapse in mice. Addict. Biol. 2017;23:154\u2013164. doi: 10.1111/adb.12495.", "ArticleIdList": ["10.1111/adb.12495", "28194850"]}, {"Citation": "Cabrera C.L.R., Keir-Rudman S., Horniman N., Clarkson N., Page C. The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination. Pulm. Pharmacol. Ther. 2021;69:102047. doi: 10.1016/j.pupt.2021.102047.", "ArticleIdList": ["10.1016/j.pupt.2021.102047", "34082108"]}, {"Citation": "Hlo\u017eek T., Uttl L., Kade\u0159\u00e1bek L., Bal\u00edkov\u00e1 M., Lhotkov\u00e1 E., Horsley R.R., Nov\u00e1kov\u00e1 P., \u0160\u00edchov\u00e1 K., \u0160tefkov\u00e1 K., Tyl\u0161 F., et al. Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC. Eur. Neuropsychopharmacol. 2017;27:1223\u20131237. doi: 10.1016/j.euroneuro.2017.10.037.", "ArticleIdList": ["10.1016/j.euroneuro.2017.10.037", "29129557"]}, {"Citation": "Bardelmeijer H.A., Ouwehand M., Malingr\u00e9 M.M., Schellens J.H., Beijnen J.H., Van Tellingen O. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut. Cancer Chemother. Pharmacol. 2001;49:119\u2013125. doi: 10.1007/s00280-001-0394-2.", "ArticleIdList": ["10.1007/s00280-001-0394-2", "11862425"]}, {"Citation": "Nagai K., Watanabe K., Narimatsu S., Gohda H., Matsunaga T., Yamamoto I., Yoshimura H. In Vitro Metabolic Formation of a New Metabolite, 6.BETA.-Hydroxymethyl.DELTA.9-tetrahydrocannabinol from Cannabidiol through an Epoxide Intermediate and Its Pharmacological Effects on Mice. Biol. Pharm. Bull. 1993;16:1008\u20131013. doi: 10.1248/bpb.16.1008.", "ArticleIdList": ["10.1248/bpb.16.1008", "8287029"]}, {"Citation": "Golombek P., M\u00fcller M., Barthlott I., Sproll C., Lachenmeier D.W. Conversion of Cannabidiol (CBD) into Psychotropic Cannabinoids Including Tetrahydrocannabinol (THC): A Controversy in the Scientific Literature. Toxics. 2020;8:41. doi: 10.3390/toxics8020041.", "ArticleIdList": ["10.3390/toxics8020041", "PMC7357058", "32503116"]}, {"Citation": "Grotenhermen F., Russo E., Zuardi A.W. Even High Doses of Oral Cannabidiol Do Not Cause THC-Like Effects in Humans: Comment on Merrick et al. Cannabis and Cannabinoid Research 2016;1(1):102\u2013112. DOI: 10.1089/can.2015.0004. Cannabis Cannabinoid Res. 2017;2:1\u20134. doi: 10.1089/can.2016.0036.", "ArticleIdList": ["10.1089/can.2016.0036", "PMC5531368", "28861499"]}, {"Citation": "Nahler G., Grotenhermen F., Zuardi A.W., Crippa J.A. A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans. Cannabis Cannabinoid Res. 2017;2:81\u201386. doi: 10.1089/can.2017.0009.", "ArticleIdList": ["10.1089/can.2017.0009", "PMC5510776", "28861507"]}, {"Citation": "Palazzoli F., Citti C., Licata M., Vilella A., Manca L., Zoli M., Vandelli M.A., Forni F., Cannazza G. Development of a simple and sensitive liquid chromatography triple quadrupole mass spectrometry (LC\u2013MS/MS) method for the determination of cannabidiol (CBD), \u0394 9 -tetrahydrocannabinol (THC) and its metabolites in rat whole blood after oral administration of a single high dose of CBD. J. Pharm. Biomed. Anal. 2018;150:25\u201332. doi: 10.1016/j.jpba.2017.11.054.", "ArticleIdList": ["10.1016/j.jpba.2017.11.054", "29202305"]}, {"Citation": "Wray L., Stott C., Jones N., Wright S. Cannabidiol Does Not Convert to \u03949-Tetrahydrocannabinol in an In Vivo Animal Model. Cannabis Cannabinoid Res. 2017;2:282\u2013287. doi: 10.1089/can.2017.0032.", "ArticleIdList": ["10.1089/can.2017.0032", "PMC5744690", "29285522"]}, {"Citation": "Crippa J.A.S., Derenusson G.N., Ferrari T.B., Wichert-Ana L., Duran F.L., Martin-Santos R., Sim\u00f5es M.V., Bhattacharyya S., Fusar-Poli P., Atakan Z., et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report. J. Psychopharmacol. 2010;25:121\u2013130. doi: 10.1177/0269881110379283.", "ArticleIdList": ["10.1177/0269881110379283", "20829306"]}, {"Citation": "Agurell S., Carlsson S., Lindgren J.E., Ohlsson A., Gillespie H., Hollister L. Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia. Cell. Mol. Life Sci. 1981;37:1090\u20131092. doi: 10.1007/BF02085029.", "ArticleIdList": ["10.1007/BF02085029", "6273208"]}, {"Citation": "Nadulski T., Pragst F., Weinberg G., Roser P., Schnelle M., Fronk E.-M., Stadelmann A.M. Randomized, Double-Blind, Placebo-Controlled Study About the Effects of Cannabidiol (CBD) on the Pharmacokinetics of \u03949-Tetrahydrocannabinol (THC) After Oral Application of THC Verses Standardized Cannabis Extract. Ther. Drug Monit. 2005;27:799\u2013810. doi: 10.1097/01.ftd.0000177223.19294.5c.", "ArticleIdList": ["10.1097/01.ftd.0000177223.19294.5c", "16306858"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "5", "Day": "2"}, {"Year": "2023", "Month": "6", "Day": "1"}, {"Year": "2023", "Month": "6", "Day": "3"}, {"Year": "2023", "Month": "6", "Day": "29", "Hour": "6", "Minute": "43"}, {"Year": "2023", "Month": "6", "Day": "28", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "6", "Day": "28", "Hour": "1", "Minute": "33"}, {"Year": "2023", "Month": "6", "Day": "6"}], "PublicationStatus": "epublish", "ArticleIdList": ["37375550", "PMC10304291", "10.3390/nu15122646", "nu15122646"]}}], "PubmedBookArticle": []}